The North America Immunohistochemistry Market is projected to showcase robust growth, driven by expanding applications in diagnostics and therapeutics. With the increasing prevalence of chronic diseases and technological advancements, the market is expected to witness significant expansion between 2020 and 2035.
The economic impact of tariffs on "North America Immunohistochemistry Market".
Market Growth Drivers
Rising Prevalence of Cancer: The growth of the North America immunohistochemistry market is primarily propelled by the increasing incidence of cancer across the region. According to the American Cancer Society, cancer cases are anticipated to rise, resulting in higher demand for immunohistochemistry techniques for accurate diagnostics and personalized medicine. Companies such as Abcam and Thermo Fisher Scientific are heavily investing in developing sensitive antibodies and reagents to support oncological research and diagnostics.
Technological Advancements in Automated Staining Platforms: Another major driver is the emergence of automated immunohistochemistry platforms that enable higher throughput and reduce manual intervention. Companies like Roche Diagnostics have launched advanced automated IHC analyzers, improving workflow efficiency and reducing turnaround time for pathology labs. This has significantly improved diagnostic accuracy, encouraging broader clinical adoption.
Market Trends
Integration of Artificial Intelligence in Diagnostics: A significant trend in the North America immunohistochemistry market is the rising integration of artificial intelligence (AI) and digital pathology. Companies including Visiopharm and Akoya Biosciences have developed AI-powered image analysis software that can accurately quantify IHC results, minimize human error, and deliver faster diagnoses. This trend is poised to revolutionize cancer diagnostics and research by allowing high-throughput and reproducible analysis.
Expansion in Companion Diagnostics: The growing focus on precision medicine has pushed immunohistochemistry towards companion diagnostics, assisting physicians in identifying patients most likely to benefit from targeted therapies. For instance, Agilent Technologies has partnered with pharmaceutical firms to co-develop IHC-based companion diagnostic tests, supporting regulatory approvals for new oncology drugs and enhancing personalized treatment protocols.
Market Opportunities
Rising Investment in Biomarker Discovery: Driven by the need for early disease detection and effective therapeutics, biopharmaceutical companies such as Bio-Techne are increasing investments in biomarker discovery using IHC. This opens lucrative opportunities for reagent and antibody manufacturers in the region.
Untapped Potential in Emerging Clinical Segments: Increasing applications of immunohistochemistry in neurodegenerative, infectious diseases, and autoimmune disorders present a significant growth opportunity for market players, enabling portfolio diversification and entry into high-growth segments.
The market revenue of the North America Immunohistochemistry Market demonstrates a consistent upward trajectory from 2020 to 2035. Starting at USD 1,325 million in 2020, the market grows steadily, reaching approximately USD 1,545 million in 2023 and crossing USD 1,705 million by 2025. The trend continues with a compounded annual growth rate of 5.2%, culminating at USD 2,985 million in 2035. This upward momentum reflects sustained demand from the healthcare and research sectors, fueled by rising chronic disease prevalence and continuous technological advancements. The graphical representation of yearly revenue showcases minimal dips, indicating market stability and strong growth prospects for investors and stakeholders across the forecast period.
North America Immunohistochemistry Market by Regional Share (%) - 2025
In 2025, the United States dominates the North America Immunohistochemistry Market with a commanding 78% share, reflecting its advanced healthcare infrastructure and high research investments. Canada follows with a 14% share due to increased adoption of IHC in diagnostics and research. Mexico accounts for 5%, while other regions, including Central America and the Caribbean, share the remaining 3%. This pie chart underscores the region's concentrated market landscape, with most activity centered in the US. The significant gap between the US and other countries highlights investment opportunities for expanding market reach and catering to underpenetrated segments with tailored offerings.
Recent Developments
In April 2024, Agilent Technologies expanded its Dako Omnis platform with new high-specificity antibodies aimed at breast and lung cancer diagnostics. This launch enhances the workflow efficiency and diagnostic accuracy for pathology labs in North America, further solidifying the company’s foothold in the region’s IHC market.
In March 2024, Roche Diagnostics introduced the Ventana DP 200 slide scanner integration with its cloud-based pathology solutions, allowing seamless digitalization and remote analysis of immunohistochemistry slides. The move supports telepathology initiatives across smaller labs and rural clinics, addressing access challenges and boosting early disease detection.
In February 2024, Thermo Fisher Scientific announced a collaboration with Mayo Clinic to develop novel multiplexed IHC assays for oncology biomarkers. This partnership aims to accelerate biomarker discovery and clinical validation from clinical trials, reinforcing the commitment to precision medicine and improved patient outcomes.
Press Releases